EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit

Immunomagnetic positive selection cell isolation kit
EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit

Immunomagnetic depletion of human CD25+ cells

1 x 10^9 cells
Catalog # 17861
711 USD
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more
Required Products
  1. EasySep™ Magnet
    EasySep™ Magnet

    Magnet for column-free immunomagnetic separation

  2. EasySep™ Buffer
    EasySep™ Buffer

    Cell separation buffer


The EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit is designed to deplete CD25+ cells from fresh peripheral blood mononuclear cells or lysed leukapheresis samples. CD25+ cells are targeted with Tetrameric Antibody Complexes recognizing CD25 and dextran-coated magnetic particles. Labeled cells are separated using an EasySep™ magnet without the use of columns. Labeled cells remain in the tube while unlabeled cells are poured off. The CD25 antigen is expressed on regulatory T cells and activated T and B cells.
• Fast, easy-to-use and column-free
• Up to 1.3 log depletion of CD25+ cells
• Up to 98% purity
EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit (Catalog #17861)
    • EasySep™  Human Pan-CD25 Positive Selection and Depletion Cocktail, 1 mL
    • EasySep™ Dextran RapidSpheres™ 50100, 2 x 1 mL
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
Cell Isolation Kits
Cell Type
T Cells, T Cells, CD4+, T Cells, Regulatory
Sample Source
Selection Method
Cell Isolation
Area of Interest

Related Products

Labeling Antibodies

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit
Catalog #
Lot #
Document Type
Safety Data Sheet
Product Name
EasySep™ Human Pan-CD25 Positive Selection and Depletion Kit
Catalog #
Lot #

Educational Materials(9)

Tools For Your Immunology Research
Cell Enrichment Prior to Cell Sorting
EasySep™ Cell Separation Technology
Human Immune Cytokines
Frequencies of Cell Types in Human Peripheral Blood
Regulatory T Cells
How EasySep™ Magnetic Cell Separation Technology Works: Fast and Easy Cell Isolation
How to Isolate PBMCs from Whole Blood Using Density Gradient Centrifugation (Ficoll™ or Lymphoprep™)
Isolate Cells with a Simple Pour-Off: EasySep™ Cell Separation Technology

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications


CD25 cell depletion results using EasySep™

Starting with fresh PBMCs, the CD25+ cell content of the depleted fraction typically ranges from 2 - 5%. In the above example, the purities of the start and final depleted fractions are 14.5% and 2.2%, respectively, with a 1.3 log depletion of CD25+ cells. Using the optional positive selection protocol, the CD25+ cell content of the isolated fraction typically ranges from 81 - 98% (data not shown).

Publications (2)

Acta neuropathologica communications 2017 dec CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons. M. Ortiz-Virumbrales et al.


Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2 (PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2 N141I mutation displayed an increase in the A$\beta$42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2 N141I lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2 N141I BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A$\beta$42/40 was also normalized following CRISPR/Cas-mediated correction of the PSEN2 N141I mutation. The genome editing data confirms the robust consistency of mutation-related changes in A$\beta$42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.
Scientific reports 2017 AUG Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Albert BJ et al.


Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through the administration of synergistic combinations of latency reversing agents (LRAs), such as histone deacetylase (HDAC) inhibitors and protein kinase C (PKC) modulators, provides a promising strategy to reduce if not eradicate the viral reservoir. Here, we demonstrate that largazole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs. Significantly, these isoform-targeted HDAC inhibitors synergize with PKC modulators, namely bryostatin-1 analogues (bryologs). Implementation of this unprecedented LRA combination induces HIV-1 reactivation to unparalleled levels and avoids global T-cell activation within resting CD4+ T-cells.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.